COVID-19 second-generation vaccine research
Support second-generation COVID-19 vaccine research at Burnet.
Support COVID-19 second-generation vaccine research at Burnet.
Support second-generation COVID-19 vaccine research at Burnet.
Support COVID-19 second-generation vaccine research at Burnet.
Worldwide, TB is the leading cause of infectious diseases deaths. Indonesia is a World Health Organization high burden country for TB, Multi-Drug Resistant TB and TB/HIV. In 2017 an estimated eight percent of the worlds TB cases occurred in Indonesia.
Indonesia’s current response to TB is unlikely to be sufficient to achieve drastic and rapid reductions in the disease burden to meet global END TB targets. This project, in partnership with Gadjah Mada University and local partners, will implement the Zero TB Initiatives comprehensive approach to control and eliminate TB in Yogyakarta Province, Indonesia. It will utilise the principles of the approach, searching actively for TB cases, treating TB effectively and preventing or treating exposure; search-treat-prevent.
Ongoing
Utilising a mobile TB service to screen 1000 participants in high-risk settings in Yogyakarta City and Kulon Progo Districts, Yogyakarta, Indonesia.
For any general enquiries relating to this project, please contact:
Infectious Diseases Specialist, TB Elimination and Implementation Science
To achieve better health for vulnerable communities in Australia and internationally by accelerating the translation of research, discovery and evidence into sustainable health solutions.
85 Commercial Road, Melbourne
VIC, 3004, Australia
Receive updates and IMPACT magazine.
Copyright © 2021 Burnet Institute. ABN: 49 007 349 984
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung and Wurundjeri people and we offer our respects to the elders past and present.
We recognise and respect the cultural heritage of this land.
